Wuzhou Pharmaceutical Co., Ltd., a subsidiary of Zhongheng group, invested 320m in oral insulin pharmaceutical company oramed

Zhongheng once again increased its stake in oramed, an Israeli pharmaceutical company invested in before, and obtained the patent right of the other party's oral insulin in China On July 3, Zhongheng group announced that Wuzhou pharmaceutical, the holding subsidiary of the group, would invest US $12 million in oramed pharmaceuticals Inc to acquire 10% of the current equity of the other party At the same time, we will pay $40 million to oramed Ltd in two phases to obtain the exclusive production, sales license and related intellectual property rights of oral insulin ormd-0801 of the other party in China The two investments totaled $52 million, or about 320 million yuan This is not the first time that Zhongheng has invested in this Israeli pharmaceutical company In August 2014, Wuzhou pharmaceutical invested $5 million in oramed Before that, Wuzhou Pharmaceutical Co., Ltd held 6.537% of the shares of oramed After the capital increase of $12 million, it will acquire another 10% of the shares On July 2, oramed just announced the first case of IIB Oramed company was listed on Nasdaq stock market in May 2007 Its main business is to develop drugs and treatment schemes for diabetes mellitus 3 through its subsidiary oramed Co., Ltd., mainly including oral insulin (ormd-0801), oral GLP-1 analog (ormd-0901) and the combination of the two drugs (ormd0801 + 0901) At present, the oral insulin (ormd-0801) project has started the phase B clinical study of FDA in the United States; the oral GLP-1 analog (ormd-0901) project is in the pre clinical study stage News extension: oramed Israel and Zhongheng group promote the construction of oral insulin project Wuzhou Municipal People's government release time: 2014-12-14 recently, nadav Kidron, chief executive of oramed Israel, and his party came to Zhongheng group for investigation and discussion to promote further cooperation of oral insulin project Accompanied by Xu Shuqing, chairman of Zhongheng group, and relevant senior executives, nadav Kidron and his party visited the Wuzhou pharmaceutical production base and xueshutong production workshop of Zhongheng group Later, the two sides held a forum to discuss how to implement the cooperation of oral insulin project Nadav Kidron mainly introduced the progress of oral insulin in clinical research at present, as well as the ideas and ideas of market development and sales cooperation in the future, and believed that Zhongheng group had a high level and strength in the field of drugs, and cooperation with Zhongheng group was the right choice and full of confidence in the cooperation between the two sides Xu Shuqing introduced the strength level of Zhongheng group in drug management, R & D, production and sales, strategic thinking, direction and goal of future development, and emphasized the importance and expectation of Zhongheng group for cooperation with oramed company.